407 related articles for article (PubMed ID: 2963622)
21. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation.
Van Ryn-McKenna J; Ofosu FA; Hirsh J; Buchanan MR
Br J Haematol; 1989 Feb; 71(2):265-9. PubMed ID: 2522314
[TBL] [Abstract][Full Text] [Related]
22. The anticoagulant activity of dermatan sulphates: evidence against the involvement of antithrombin III.
Kindness G; Long WF; Williamson FB
Br J Pharmacol; 1981 Jan; 72(1):81-8. PubMed ID: 7225714
[TBL] [Abstract][Full Text] [Related]
23. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
[No Abstract] [Full Text] [Related]
24. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa.
Ofosu FA; Hirsh J; Esmon CT; Modi GJ; Smith LM; Anvari N; Buchanan MR; Fenton JW; Blajchman MA
Biochem J; 1989 Jan; 257(1):143-50. PubMed ID: 2920007
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic effect of sulphated and nonsulphated glycosaminoglycans and polysaccharides in the chick embryo chorioallantoic membrane.
Hahnenberger R; Jakobson AM
Glycoconj J; 1991 Aug; 8(4):350-3. PubMed ID: 1726778
[TBL] [Abstract][Full Text] [Related]
26. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
Merton RE; Thomas DP
Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
[TBL] [Abstract][Full Text] [Related]
27. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
[TBL] [Abstract][Full Text] [Related]
28. Release of diamine oxidase into plasma by glycosaminoglycans in rats.
D'Agostino L; Pignata S; Daniele B; Ventriglia R; Ferrari G; Ferraro C; Spagnuolo S; Lucchelli PE; Mazzacca G
Biochim Biophys Acta; 1989 Dec; 993(2-3):228-32. PubMed ID: 2512987
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082.
Ofosu FA; Fareed J; Smith LM; Anvari N; Hoppensteadt D; Blajchman MA
Eur J Biochem; 1992 Jan; 203(1-2):121-5. PubMed ID: 1730217
[TBL] [Abstract][Full Text] [Related]
30. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
Hoppensteadt D; Walenga JM; Fareed J
Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
Ofosu FA
Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
[TBL] [Abstract][Full Text] [Related]
32. Thrombin-mediated activation of endogenous factor XI in plasma in the presence of physiological glycosaminoglycans occurs only with high concentrations of thrombin.
Wuillemin WA; Mertens K; ten Cate H; Hack CE
Br J Haematol; 1996 Feb; 92(2):466-72. PubMed ID: 8603018
[TBL] [Abstract][Full Text] [Related]
33. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin.
Ofosu FA; Sie P; Modi GJ; Fernandez F; Buchanan MR; Blajchman MA; Boneu B; Hirsh J
Biochem J; 1987 Apr; 243(2):579-88. PubMed ID: 2443128
[TBL] [Abstract][Full Text] [Related]
34. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans.
Cosmi B; Cini M; Legnani C; Pancani C; Calanni F; Coccheri S
Thromb Res; 2003 Mar; 109(5-6):333-9. PubMed ID: 12818259
[TBL] [Abstract][Full Text] [Related]
35. Coagulation protein function: enhancement of the anticoagulant effect of acetaldehyde by sulfated glycosaminoglycans.
Brecher AS; Adamu MT
Dig Dis Sci; 2001 Sep; 46(9):2033-42. PubMed ID: 11575460
[TBL] [Abstract][Full Text] [Related]
36. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II.
Tovar AM; de Mattos DA; Stelling MP; Sarcinelli-Luz BS; Nazareth RA; Mourão PA
Biochim Biophys Acta; 2005 Apr; 1740(1):45-53. PubMed ID: 15878740
[TBL] [Abstract][Full Text] [Related]
37. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
[TBL] [Abstract][Full Text] [Related]
38. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm.
Pacheco RG; Vicente CP; Zancan P; Mourão PA
Blood Coagul Fibrinolysis; 2000 Sep; 11(6):563-73. PubMed ID: 10997797
[TBL] [Abstract][Full Text] [Related]
39. Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants.
Monagle P; Berry L; O'Brodovich H; Andrew M; Chan A
J Biol Chem; 1998 Dec; 273(50):33566-71. PubMed ID: 9837939
[TBL] [Abstract][Full Text] [Related]
40. Glycosaminoglycans in early chick embryo.
Skandalis SS; Theocharis AD; Papageorgakopoulou N; Zagris N
Int J Dev Biol; 2003 May; 47(4):311-4. PubMed ID: 12755338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
